أعرض في EDS

1653P Cabozantinib (C) vs placebo (P) in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who progressed after prior VEGFR-targeted therapy: Outcomes by duration of prior lenvatinib (L) treatment

التفاصيل البيبلوغرافية
العنوان:	1653P Cabozantinib (C) vs placebo (P) in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who progressed after prior VEGFR-targeted therapy: Outcomes by duration of prior lenvatinib (L) treatment
المؤلفون:	M.S. Brose, J.A. Krajewska, F. Vaisman, A.O. Hoff, E. Hitre, J. Oliver, D.S. Williamson, N. Berry, J. Capdevila Castillon
المصدر:	Annals of Oncology. 33:S1297-S1298
بيانات النشر:	Elsevier BV, 2022.
سنة النشر:	2022
مصطلحات موضوعية:	Oncology, Hematology
تدمد:	0923-7534
URL الوصول:	https://explore.openaire.eu/search/publication?articleId=doi_________::7fccc47b2a3a1fbc8d32d76a9a0b5b01 https://doi.org/10.1016/j.annonc.2022.07.1733
حقوق:	CLOSED
رقم الأكسشن:	edsair.doi...........7fccc47b2a3a1fbc8d32d76a9a0b5b01
قاعدة البيانات:	OpenAIRE

الوصف
تدمد:	09237534